Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Formal Collaboration Agreements between the University of Oxford and the Oxford Radcliffe Hospitals NHS Trust

The University of Oxford and the Oxford Radcliffe Hospitals NHS Trust have signalled their intention to cement and strengthen their collaboration in research, teaching and patient care by agreeing terms for a formal and legally-binding relationship.

There has been a long history of joint working between the University of Oxford and the NHS hospitals in Oxford, greatly benefitting both patients and the wider community.

 

Existing collaborations include the ambitious research programmes established through the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Oxford Radcliffe Hospitals NHS Trust (ORH) and at the Biomedical Research Unit in musculoskeletal disease at the Nuffield Orthopaedic Centre NHS Trust (NOC). These set the standard in translating science and research into new and better NHS clinical care.

The University and the Oxford Radcliffe Hospitals NHS Trust have agreed to formalise their relationship by entering into a Joint Working Agreement and a Trade Mark Licence. These will provide a formal structure and governance to the relationship between the two organisations, enhancing the ability to share ideas and activities and to function as a joint venture committed to the pursuit of excellence in patient care, research and education.

The intent is to complete these agreements at the same time as the ORH’s integration with the Nuffield Orthopaedic Centre NHS Trust, which is planned to take place later in the year (subject to approval by the Secretary of State for Health).

Professor Andrew Hamilton, Vice-Chancellor of Oxford University said: “We welcome this opportunity to strengthen our relationship with the hospitals further, forming the tight links which support the best teaching of medical students, excellence in medical research and the delivery of quality healthcare.

“The University has long worked closely with the Oxford Radcliffe Hospitals. These new agreements will recognise our strong mutual interests and will see us extend the way we work together, with benefits for the care which patients receive now and research on the treatments they may receive in the future.”

Sir Jonathan Michael, Chief Executive of the Oxford Radcliffe Hospitals NHS Trust, said: “The collaboration between the Oxford Radcliffe Hospitals and the University underpins the quality of the care that is provided to patients; to the delivery of high-quality research bringing innovation from the laboratory bench to the bedside; and the delivery of high-quality education and training of doctors. The decision by the Trust Board and the University Council to enter into these formal agreements reinforces this very important relationship.”

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.